Population Immunity Against COVID-19 in The United States Part 1

Background: As of 28 July 2021, 60% of adults in the United States had been fully vaccinated against COVID-19, and more than 34 million cases had been reported. Given the uncertainty regarding undocumented infections, the population level of immunity against COVID-19 in the United States remains undetermined.

There is a close relationship between immunity levels and memory. This is because a healthy body allows us to process and remember information better, and immunity is necessary to maintain a healthy body.

First, immunity helps us prevent disease. Illness is one of the biggest threats to our bodies, and when we are sick, our bodies divert our energy away from viruses and bacteria. In this case, our memory is affected. When our body's energy is devoted to dealing with the illness, we are less able to focus on the task of memory.

Second, a healthy immune system helps us stay awake and focused. When our bodies feel uncomfortable and tired, we often feel lightheaded, unfocused, and distracted. When we feel good, our brains can process information and memories with greater focus and clarity.

Finally, a healthy immunity level can lower our stress levels. Stress is a common psychological problem that affects our cognitive abilities and memory. By maintaining a healthy body, we can handle stress better and have better memory and cognitive abilities.

Overall, maintaining healthy immunity levels is an effective way to improve our memory and cognitive abilities. By focusing on healthy eating, exercise, and sleep, we can effectively reduce the threat of illness and stress, thereby maintaining a healthy body and a sharp mind. It can be seen that we need to improve memory, and Cistanche deserticola can significantly improve memory, because Cistanche deserticola has antioxidant, anti-inflammatory, and anti-aging effects, which can help reduce oxidation and inflammatory reactions in the brain, thereby protecting the health of the nervous system. In addition, Cistanche deserticola can also promote the growth and repair of nerve cells, thereby enhancing the connectivity and function of neural networks. These effects can help improve memory, learning ability, and thinking speed, and may also prevent the development of cognitive dysfunction and neurodegenerative diseases.

Click know supplements to improve memory

Objective: To estimate the population immunity, defined as the proportion of the population that is protected against SARS-CoV-2 infection due to prior infection or vaccination.

Design: Statistical and simulation modeling to estimate overall and age-specific population immunity.

Setting: United States.

Participants: Simulated age-stratified population representing U.S. demographic characteristics.

Measurements: The true number of SARS-CoV-2 infections in the United States was inferred from data on reported deaths using age-specific infection-fatality rates (IFRs). Taking into account the estimates for vaccine effectiveness and protection against reinfection, the overall population immunity was determined as the sum of protection levels in vaccinated persons and those who were previously infected but not vaccinated.

Results: Using age-specific IFR estimates from the Centers for Disease Control and Prevention, it was estimated that as of 15 July 2021, 114.9 (95% credible interval [CrI], 103.2 to 127.4) million persons had been infected with SARS-CoV-2 in the United States. 

The mean overall population immunity was 62.0% (CrI, 58.4% to 66.4%). Adults aged 65 years or older were estimated to have the highest immunity level (77.2% [CrI, 76.2% to 78.6%]), and children younger than 12 years had the lowest immunity level (17.9% [CrI, 14.4% to 21.9%]).

Limitation: Publicly reported deaths may underrepresent actual deaths.

Conclusion: As of 15 July 2021, the U.S. population's immunity against COVID-19 may still have been insufficient to contain the outbreaks and safely revert to pre-pandemic social behavior.

Primary Funding Source: National Science Foundation, National Institutes of Health, Notsew Orm Sands Foundation, Canadian Institutes of Health Research, and Natural Sciences and Engineering Research Council of Canada.

Population immunity against COVID-19 through a combination of vaccination and infection is fundamental to epidemiologic trajectories, the potential for emerging variants to spread, and the likelihood of disease control. 

In the United States, as of 28 July 2021, more than 34 million COVID-19 cases have been reported since the beginning of the pandemic. Vaccine development and deployment have proceeded rapidly, and more than 340 million doses have been administered, with 60% of the adult population fully vaccinated. 

Concurrently, the daily number of new cases has decreased dramatically since the peak of the pandemic in January 2021, although population pockets with low vaccination coverage are experiencing upticks in cases as the highly contagious Delta (B.1.617.2) variant spreads across the United States. 

The lack of adherence to nonpharmaceutical interventions before the attainment of sufficient population immunity carries a significant risk for another wave of COVID-19 cases and deaths. Previous studies and news reports have primarily focused on vaccination as a path to achieving herd immunity (1–3). However, immunity in the population is gained from both natural infection and vaccination. 

Given the uncertainty about unreported cases, including asymptomatic infections, questions remain about the true number of infections throughout the pandemic and the level of population immunity achieved in the United States thus far. In this study, we estimated overall and age-specific levels of population immunity against COVID-19 in the United States.

Model Overview

We used statistical and simulation modeling as well as reported deaths in the United States to estimate the total number of infections since the start of the pandemic. We then combined these with estimates of vaccination coverage and real-world vaccine effectiveness to calculate the overall and age-stratified population immunity in the United States. Simulation codes for reproducibility can be found at https://github.com/affans/c19popimmunity.

Data Sources

We used reported daily COVID-19 deaths for each age group (4, 5) in the United States from 21 January 2020 to 15 July 2021. Information on coverage of first and second vaccine doses, stratified by age groups, was obtained from the Centers for Disease Control and Prevention (CDC) (6). Infection-fatality rate (IFR) estimates and other data inputs were obtained from published literature and the CDC (Tables 1 to 3).

Estimating Total Infections

The total number of infections was estimated from reported daily COVID-19 deaths in the United States (4, 5) using 500 Monte Carlo simulations. Specifically, the reported death total Dt on each day t was used to impute the number of infections, using estimates of the IFR for COVID-19. The IFR, by definition, represents the ratio of the cumulative deaths attributable to the disease to the total number of infections (both symptomatic and asymptomatic). 

To account for the uncertainty in IFR estimates, we sampled IFR values for model inputs from age-specific log-normal distributions, with the mean parameters informed by estimates from 3 sources: the CDC (7), an analysis of the early stages of the pandemic in China (8), and a multinational study combining death data from 45 countries and the results of 22 seroprevalence studies (9) (Table 1). 

The scale parameter of the log-normal distributions was set to 0.1, which allowed for the range of IFR estimates to be considered in the model sampling. The number of infections Nt in each age group was then calculated as Dt/ IFR.

Accounting for the Lag Time Between Infection and Death

For each inferred infection, whether it resulted in recovery or death, we estimated the lag time t 0 so that the infection occurred t t 0 days before the reported death on day t. The lag time was calculated as the sum of 2 independent intervals: the incubation period, which estimates the time from infection to onset of symptoms, and the time from symptom onset to death (Table 2). 

These intervals were sampled for each infection, accounting for the uncertainty of parameters in their corresponding distributions. The number of infections Nt on any day t was then calculated as the sum of all infections associated with reported deaths at time t > t and all infection lag times t 0 such that t t 0 = t.

Adjustment for Double-Counting

To prevent double-counting in our estimates of population immunity, we derived the proportion P of previously infected persons who were vaccinated (Table 3). In the absence of information on prior infection for vaccinated persons, we probabilistically calculated the proportion P for each age group via Monte Carlo replications. In each replication, we randomly assigned infections to a computational vector of population size for each age group, corresponding to the cumulative number of infections inferred from the process described earlier. 

Similarly, fully vaccinated persons were assigned randomly to a vector of the same size, according to the reported vaccination coverage of the age group. We then determined the overlap between these vectors to identify persons who were both vaccinated and infected. 

We iterated this process 1000 times to obtain the mean and the lower and upper bounds of the proportion P and to determine the number of persons who were infected but not vaccinated. Given the CDC's recommendation to delay vaccination by 3 months after infection, this part of the analysis was done for those who were infected 90 days before 15 July 2021 (16).

Analysis of Population Immunity

We estimated the naturally acquired protection level by adjusting the cumulative number of infections RNt for the level of protection against reinfection conferred by a previous infection (Table 2). 

For vaccine-induced population immunity, we considered the proportion of vaccinated persons who received the Pfizer-BioNTech (58%) and Moderna (42%) vaccines (17) and their effectiveness after the first and second doses of each (Table 2). 

We calculated population immunity as the sum of naturally acquired protection levels in previously infected but unvaccinated persons and levels of vaccine-induced protection in partially and fully vaccinated persons.

For more information:1950477648nn@gmail.com